References
[1] Global Cancer Observatory (http://gco.iarc.fr/) International Agency Research on Cancer 2022
[2] SEER 17 2012–2018, All Races, Both Sexes by SEER Combined Summary Stage. https://seer.cancer.gov/statfacts/html/pancreas.html
[3] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® )Pancreatic Adenocarcinoma Version 1.2022-February 24,2022.https://www.nccn.org/professionals/ physician_gls/pdf/pancreatic.
[4] Webber C, Gospodarowicz M, Sobin LH, Wittekind C, et al. Improving the TNM classification: findings from a 10-year continuous literature review. Int J Cancer. 2014 Jul 15;135(2):371-8. doi: 10.1002/ijc.28683. PMID: 24921087.
[5] van Roessel S, Kasumova GG, Verheij J, et al. International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer. JAMA Surg. 2018 Dec 1;153(12):e183617. doi: 10.1001/jamasurg.2018.3617. Epub 2018 Dec 19. Erratum in: JAMA Surg. 2019 Feb 20;: PMID: 30285076; PMCID: PMC6583013.
[6] Shin DW, Lee JC, Kim J, et al. Validation of the American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma. Eur J Surg Oncol. 2019 Nov;45(11):2159-2165. doi: 10.1016/j.ejso.2019.06.002. Epub 2019 Jun 3. PMID: 31202572.
[7] Kwon W, He J, Higuchi R, et al. Multinational validation of the American Joint Committee on Cancer 8th edition pancreatic cancer staging system in a pancreas head cancer cohort. J Hepatobiliary Pancreat Sci. 2018 Sep;25(9):418-427. doi: 10.1002/jhbp.577. PMID: 30118171.
[8] Abdel-Rahman O. Evaluation of the 8th AJCC staging system for pathologically versus clinically staged pancreatic adenocarcinoma: A time to revisit a dogma? Hepatobiliary Pancreat Dis Int. 2018 Feb;17(1):64-69. doi: 10.1016/j.hbpd.2018.01.014. Epub 2018 Jan 31. PMID: 29428107.
[9] Schouten TJ, Daamen LA, Dorland G, et al; Dutch Pancreatic Cancer Group. Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer. Ann Surg Oncol. 2022 Sep;29(9):5988-5999. doi: 10.1245/s10434-022-11664-4. Epub 2022 Apr 25. Erratum in: Ann Surg Oncol. 2022 Jul 7;: PMID: 35469113; PMCID: PMC9356941.
[10] Oba A, Croce C, Hosokawa P, et al. Prognosis Based Definition of Resectability in Pancreatic Cancer: A Road Map to New Guidelines. Ann Surg. 2022 Jan 1;275(1):175-181. doi: 10.1097/SLA.0000000000003859. PMID: 32149822.
[11] Chen YT, Huang ZP, Zhou ZW, et al. Equipping the American Joint Committee on Cancer staging for resectable pancreatic ductal adenocarcinoma with tumor grade: a recursive partitioning analysis. Med Oncol. 2016 Nov;33(11):122. doi: 10.1007/s12032-016-0839-4. Epub 2016 Oct 11. PMID: 27730526; PMCID: PMC5059399.
[12] Kim SI, Cassella CR, Byrne KT. Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes. Front Immunol. 2021 Feb 1;11:629722. doi: 10.3389/fimmu.2020.629722. PMID: 33597954; PMCID: PMC7882695.
[13] Kinny-Köster B, Habib JR, Wolfgang CL, et al. Favorable tumor biology in locally advanced pancreatic cancer-beyond CA19-9. J Gastrointest Oncol. 2021 Oct;12(5):2484-2494. doi: 10.21037/jgo-20-426. PMID: 34790409; PMCID: PMC8576224.
[14] Dall’Olio FG, Marabelle A, Caramella C, et al. Tumour burden and efficacy of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2022 Feb;19(2):75-90. doi: 10.1038/s41571-021-00564-3. Epub 2021 Oct 12. PMID: 34642484.
[15] König AK, Gros H, Hinz U, et al. Refined prognostic staging for resected pancreatic cancer by modified stage grouping and addition of tumour grade. Eur J Surg Oncol. 2022 Jan;48(1):113-120. doi: 10.1016/j.ejso.2021.07.020. Epub 2021 Jul 26. PMID: 34344573.
[16] Macías N, Sayagués JM, Esteban C, et al. Histologic Tumor Grade and Preoperative Bilary Drainage are the Unique Independent Prognostic Factors of Survival in Pancreatic Ductal Adenocarcinoma Patients After Pancreaticoduodenectomy. J Clin Gastroenterol. 2018 Feb;52(2):e11-e17. doi: 10.1097/MCG.0000000000000793. PMID: 28059940.
[17] Kang YM, Wang H, Li R, et al. Prognostic Role of Carbohydrate Antigen 19 to 9 in Predicting Survival of Patients With Pancreatic Cancer: A Meta-Analysis. Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211043030. doi: 10.1177/15330338211043030. PMID: 34617852; PMCID: PMC8642114.
[18] Berger AC, Meszoely IM, Ross EA, et al.Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2004;11:644–9.
[19] Ferrone CR, Finkelstein DM, Thayer SP, et al. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006;24:2897–902.
[20] Waraya M, Yamashita K, Katagiri H, et al. Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer. Ann Surg Oncol.2009;16:1231–40.
[21] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® )Pancreatic Adenocarcinoma Version 1.2022-February 24, 2022. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.
[22] Murai J, Soga S, Saito H, et al.(2013) Study on the mechanism causing elevation of serum CA19-9 levels in diabetic patients. Endocr J 60:885–891.
[23] Roback, J., et al. AABB Technical Manual. 16th edition.. American Association of Blood Banks;2008.
[24] Tempero MA, et al. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987; 47(20):5501–3. [PubMed: 3308077]
[25] Uchida E, et al. Correlative studies on antigenicity of pancreatic cancer and blood group types.Cancer Detect Prev Suppl. 1987:145–8. [PubMed: 3319143]
[26] Pleskow DK, Berger HJ, Gyves J, et al. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med. 1989 May 1;110(9):704-9. doi: 10.7326/0003-4819-110-9-704. PMID: 2930108.
[27] Ni XG, Bai XF, Mao YL, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol. 2005 Mar;31(2):164-9. doi: 10.1016/j.ejso.2004.09.007. PMID: 15698733.
[28] Hartwig W, Strobel O, Hinz U, et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol. 2013 Jul;20(7):2188-96. doi: 10.1245/s10434-012-2809-1. Epub 2012 Dec 18. PMID: 23247983.
[29] Kumar V, Fausto N, Abbas A. Robbins and Cotran pathologic basis of disease. 7th ed. Philadelphia: Saunders; 2004.
[30] Telloni SM. Tumor Staging and Grading: A Primer. Methods Mol Biol. 2017;1606:1-17. doi: 10.1007/978-1-4939-6990-6_1. PMID: 28501990.
[31] Macías N, Sayagués JM, Esteban C, et al. Histologic Tumor Grade and Preoperative Bilary Drainage are the Unique Independent Prognostic Factors of Survival in Pancreatic Ductal Adenocarcinoma Patients After Pancreaticoduodenectomy. J Clin Gastroenterol. 2018 Feb;52(2):e11-e17. doi: 10.1097/MCG.0000000000000793. PMID: 28059940.
[32] König AK, Gros H, Hinz U, et al. Refined prognostic staging for resected pancreatic cancer by modified stage grouping and addition of tumour grade. Eur J Surg Oncol. 2022 Jan;48(1):113-120. doi: 10.1016/j.ejso.2021.07.020. Epub 2021 Jul 26. PMID: 34344573.